Developer docs
API playgroundTry for free, no card

Search company profiles

LongGame

Full company profile

uuid0005qbx

Namestring
LongGame
Legal namestring
LongGame Advisors Ltd
Websiteurl
longgame.vc
Company typeenum
Private
Founded yearint
2024
Descriptiontext

LongGame is a UK-based venture capital fund investing exclusively in pre-seed and seed-stage longevity biotech companies. It is structured as LongGame Advisors Ltd, incorporated in England and Wales (Company No. 15981536), operating as an Appointed Representative of Robert Quinn Advisory LLP under FCA authorization, on behalf of LongGame Fund I L.P., a Jersey-domiciled investment vehicle. The firm applies a stated hard rule that every portfolio company must have the potential to extend healthy human lifespan by at least 10+ years, and it focuses on scalable solutions intended for global populations rather than wealthy-only clientele.

The fund deploys capital across approximately 17 portfolio companies spanning a broad set of longevity-relevant modalities: novel therapeutics (Ladder Bio's Spiroligomers, Deciduous senolytics, Revel Pharma crosslink therapies), gene and cell therapies (Cirrus Therapeutics, Oisin Bio's Fusogenix PLV platform, Syntax Bio, Immune Bridge), regenerative medicine and synthetic biology (Renewal Bio, Totality Biosciences, R3 Bio's organ sacks), age-related disease platforms (Repair Biotechnologies for cardiovascular disease, Aperture Therapeutics for neurodegeneration, Vincere Bio's USP30 mitophagy program), induced-proximity drug discovery (General Proximity's OmniTAC platform), IVF screening (Herasight), protein engineering tooling (Adaptyv Bio), and consumer-facing longevity distribution (Lucis Life, Enhanced Games). LongGame does not develop proprietary underlying technology itself; its core offering is capital plus operational support, delivered via the L³ Longevity Launchpad open call program and Demo Days.

The business model is standard venture fund economics: management fees on committed LP capital and future carried interest on exits from portfolio companies. Revenue is not publicly disclosed and the customer base is restricted to professional clients and eligible counterparties. Distribution is community-led, combining a website, Substack newsletter, the L³ open call for founders, and co-investment syndicates with firms such as Draper Associates and Mayo Clinic on portfolio follow-on rounds.

Short descriptiontext

LongGame is a UK-based pre-seed and seed-stage venture capital fund that invests exclusively in longevity biotech companies with the potential to extend healthy human lifespan by 10+ years, serving professional LPs through LongGame Fund I L.P. and supporting founders via its L³ Longevity Launchpad program.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
1–10
akta.pro rankint
HeadquartersLondon, United Kingdom
HQ citystring
London
HQ countrystring
United Kingdom
HQ regionstring
Europe
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
venture capital funding, seed-stage investing, biotech investment fund, longevity biotech investing, pre-seed capital
NAICS code2 codes
  • Portfolio Management and Investment Advice52394
  • Portfolio Management and Investment Advice523940
SIC code1 code
  • Investment Advice6282
Product category
Venture Capital / Investment Management
Social media profiles2 records
GTM motion2 records

Each record includes

Type, Description, Source

Revenue model1 record
1Fund Management Fees
TypeLicensing Royalties
Description

LongGame operates as a venture capital fund managing capital from limited partners (LPs). The fund earns returns through equity appreciation in portfolio companies, typically realized through exits, acquisitions, or IPOs of invested companies.

longgame.vc
Marketing channels5 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels1 record

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Personnel, Operations, Marketing or Sales, Technology or R&D, Others
GTM typeB2B
B2B
Offering typeServices
Services
Brand1 record
1L³ (LongGame's Longevity Launchpad)
Description

An open call program for scientists, builders, and contrarian thinkers working on the hardest problems in longevity, offering investment and hands-on support.

longgame.vc
Core offering1 text field

LongGame operates a pre-seed and seed-stage venture capital fund (LongGame Fund I L.P.) that invests exclusively in longevity biotech companies developing technologies with the potential to extend healthy human lifespan by at least 10+ years. The firm combines equity capital with hands-on operational support to founders working on therapeutics, diagnostics, devices, and platforms at the frontier of human health and longevity. Deal sourcing and founder support are delivered through the L³ (LongGame's Longevity Launchpad) open-call program, virtual Demo Days, and direct outreach, while Limited Partner capital is raised only from professional clients and eligible counterparties.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 value
  • Every company backed must have potential to extend healthy human lifespan by at least 10+ years
Product overview1 text field

LongGame is a pre-seed and seed-stage venture capital fund investing exclusively in longevity biotech companies. The firm backs radical life extension technologies with the potential to extend healthy human lifespan by at least 10+ years, focusing on scalable solutions for global populations rather than just wealthy clients. The fund's core offering is investment capital combined with hands-on operational support through its LongGame L³ (Longevity Launchpad) program. The portfolio spans 19 companies across diverse therapeutic and technology categories including: novel therapeutic modalities (Ladder Bio with Spiroligomers™), gene therapies (Cirrus Therapeutics, Oisin Bio with Fusogenix™ PLV platform), cell therapies (Syntax Bio, Immune Bridge), senolytics (Deciduous), damage repair (Revel Pharma), mitophagy (Vincere Bio), synthetic biology (Totality Biosciences), drug discovery (General Proximity with OmniTAC platform), regenerative medicine (Renewal Bio, R3), brain aging (Aperture Therapeutics), tooling/IVF (Herasight, Adaptyv Bio), and distribution platforms (Enhanced Games, Lucis Life).

Product and service2 records
1LongGame Fund I L.P.
CategoryInvestment Fund
Description

A pre-seed and seed-stage venture capital fund investing exclusively in longevity biotech companies that have the potential to extend healthy human lifespan by at least 10+ years, with a focus on scalable solutions for global populations. Operates through LongGame Advisors Ltd (England and Wales) on behalf of LongGame Fund I L.P. (Jersey), and is available only to professional clients and eligible counterparties.

2L³ - LongGame's Longevity Launchpad
CategoryAccelerator/Program
Description

An open call program supporting founders developing therapeutics, diagnostics, devices, and platforms at the frontier of human health and longevity. Successful applicants receive investment from LongGame Fund I L.P. alongside hands-on operational support from the LongGame team.

Scale indicator3 records

Each record includes

Type, Value, Description, Source

Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight5 records

Each record includes

Type, Description

Market position
Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat4 records

Each record includes

Type, Details

Customer concentration

Classification, Details

Segment2 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile2 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
No
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles6 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
Compliance1 record

Each record includes

Name, Class, Description

Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment6 records

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

LongGame

Venture Capital / Investment Managementlonggame.vc

LongGame is a UK-based pre-seed and seed-stage venture capital fund that invests exclusively in longevity biotech companies with the potential to extend healthy human lifespan by 10+ years, serving professional LPs through LongGame Fund I L.P. and supporting founders via its L³ Longevity Launchpad program.

What LongGame does

LongGame is a UK-based venture capital fund investing exclusively in pre-seed and seed-stage longevity biotech companies. It is structured as LongGame Advisors Ltd, incorporated in England and Wales (Company No. 15981536), operating as an Appointed Representative of Robert Quinn Advisory LLP under FCA authorization, on behalf of LongGame Fund I L.P., a Jersey-domiciled investment vehicle. The firm applies a stated hard rule that every portfolio company must have the potential to extend healthy human lifespan by at least 10+ years, and it focuses on scalable solutions intended for global populations rather than wealthy-only clientele.

The fund deploys capital across approximately 17 portfolio companies spanning a broad set of longevity-relevant modalities: novel therapeutics (Ladder Bio's Spiroligomers, Deciduous senolytics, Revel Pharma crosslink therapies), gene and cell therapies (Cirrus Therapeutics, Oisin Bio's Fusogenix PLV platform, Syntax Bio, Immune Bridge), regenerative medicine and synthetic biology (Renewal Bio, Totality Biosciences, R3 Bio's organ sacks), age-related disease platforms (Repair Biotechnologies for cardiovascular disease, Aperture Therapeutics for neurodegeneration, Vincere Bio's USP30 mitophagy program), induced-proximity drug discovery (General Proximity's OmniTAC platform), IVF screening (Herasight), protein engineering tooling (Adaptyv Bio), and consumer-facing longevity distribution (Lucis Life, Enhanced Games). LongGame does not develop proprietary underlying technology itself; its core offering is capital plus operational support, delivered via the L³ Longevity Launchpad open call program and Demo Days.

The business model is standard venture fund economics: management fees on committed LP capital and future carried interest on exits from portfolio companies. Revenue is not publicly disclosed and the customer base is restricted to professional clients and eligible counterparties. Distribution is community-led, combining a website, Substack newsletter, the L³ open call for founders, and co-investment syndicates with firms such as Draper Associates and Mayo Clinic on portfolio follow-on rounds.

LongGame firmographics

Firmographics
Name
LongGame
Legal name
LongGame Advisors Ltd
Website
https://longgame.vc
Company type
Private
Founded year
2024
Operating status
Operating
Headcount range
1–10 employees
Short description
LongGame is a UK-based pre-seed and seed-stage venture capital fund that invests exclusively in longevity biotech companies with the potential to extend healthy human lifespan by 10+ years, serving professional LPs through LongGame Fund I L.P. and supporting founders via its L³ Longevity Launchpad program.
Ownership category
akta.pro rank

Where LongGame is headquartered

Location

Headquarters

HQ city
London
HQ country
United Kingdom
HQ region
Europe

Offices1 record

Markets served

LongGame business model

Business model
GTM type
B2B
Offering type
Services
Cost components
Personnel, Operations, Marketing or Sales, Technology or R&D, Others

Revenue model

  1. Fund Management Fees: LongGame operates as a venture capital fund managing capital from limited partners (LPs). The fund earns returns through equity appreciation in portfolio companies, typically realized through exits, acquisitions, or IPOs of invested companies.

Go-to-market motion2 records

Distribution channels1 record

Marketing channels5 records

LongGame product offering

Product offering

Core offering

LongGame operates a pre-seed and seed-stage venture capital fund (LongGame Fund I L.P.) that invests exclusively in longevity biotech companies developing technologies with the potential to extend healthy human lifespan by at least 10+ years. The firm combines equity capital with hands-on operational support to founders working on therapeutics, diagnostics, devices, and platforms at the frontier of human health and longevity. Deal sourcing and founder support are delivered through the L³ (LongGame's Longevity Launchpad) open-call program, virtual Demo Days, and direct outreach, while Limited Partner capital is raised only from professional clients and eligible counterparties.

Product overview

LongGame is a pre-seed and seed-stage venture capital fund investing exclusively in longevity biotech companies. The firm backs radical life extension technologies with the potential to extend healthy human lifespan by at least 10+ years, focusing on scalable solutions for global populations rather than just wealthy clients. The fund's core offering is investment capital combined with hands-on operational support through its LongGame L³ (Longevity Launchpad) program. The portfolio spans 19 companies across diverse therapeutic and technology categories including: novel therapeutic modalities (Ladder Bio with Spiroligomers™), gene therapies (Cirrus Therapeutics, Oisin Bio with Fusogenix™ PLV platform), cell therapies (Syntax Bio, Immune Bridge), senolytics (Deciduous), damage repair (Revel Pharma), mitophagy (Vincere Bio), synthetic biology (Totality Biosciences), drug discovery (General Proximity with OmniTAC platform), regenerative medicine (Renewal Bio, R3), brain aging (Aperture Therapeutics), tooling/IVF (Herasight, Adaptyv Bio), and distribution platforms (Enhanced Games, Lucis Life).

Differentiator

Problem solved

Functional benefit

Brands

  • L³ (LongGame's Longevity Launchpad): An open call program for scientists, builders, and contrarian thinkers working on the hardest problems in longevity, offering investment and hands-on support.

Products and services

  • LongGame Fund I L.P. A pre-seed and seed-stage venture capital fund investing exclusively in longevity biotech companies that have the potential to extend healthy human lifespan by at least 10+ years, with a focus on scalable solutions for global populations. Operates through LongGame Advisors Ltd (England and Wales) on behalf of LongGame Fund I L.P. (Jersey), and is available only to professional clients and eligible counterparties.
  • L³ - LongGame's Longevity Launchpad An open call program supporting founders developing therapeutics, diagnostics, devices, and platforms at the frontier of human health and longevity. Successful applicants receive investment from LongGame Fund I L.P. alongside hands-on operational support from the LongGame team.

Quantifiable outcome

  • Every company backed must have potential to extend healthy human lifespan by at least 10+ years

Companies that use LongGame

Customer profile

Segments2 records

Ideal customer profiles2 records

LongGame technology and API

Technology

Technology focussed No

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

LongGame partnerships and signals

Strategic signal

Scale indicators3 records

Recent moves6 records

Expansion highlights5 records

LongGame competitors and assessment

Company assessment

Market position

Weaknesses5 records

Competitive moat4 records

Customer concentration

LongGame social profiles

Digital presence

LongGame compliance and trust

Trust signal

Compliance1 record

LongGame financial estimates

Financial estimate

Revenue estimate

Valuation estimate

LongGame leadership team

Management profile

Number of profiles

Profiles6 records

LongGame funding detail

Funding detail

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

LongGame M&A and investment

M&A and investment

M&A

Investments6 records

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about LongGame

What does LongGame do?

LongGame operates a pre-seed and seed-stage venture capital fund (LongGame Fund I L.P.) that invests exclusively in longevity biotech companies developing technologies with the potential to extend healthy human lifespan by at least 10+ years. The firm combines equity capital with hands-on operational support to founders working on therapeutics, diagnostics, devices, and platforms at the frontier of human health and longevity. Deal sourcing and founder support are delivered through the L³ (LongGame's Longevity Launchpad) open-call program, virtual Demo Days, and direct outreach, while Limited Partner capital is raised only from professional clients and eligible counterparties.

Is LongGame a public or private company?

LongGame is a private company. It is classified as management employee owned and is currently operating.

When was LongGame founded?

LongGame was founded in 2024. It employs 1 to 10 people.

Where is LongGame based?

LongGame is headquartered in London, United Kingdom, in the Europe region.

How does LongGame make money?

One revenue line is on record: fund Management Fees.

Does LongGame have an API?

No public API is recorded for LongGame.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
MorningstarSyntax Bio Announces Expanded Series A and Leadership AppointmentsSyntax Bio announced an expanded Series A bringing total funding to over $25 million, with proceeds supporting its Cellgorithm platform and pancreatic beta cell therapy for type 1 diabetes. The company also appointed new executives and board members to strengthen leadership.BusinessinsiderLa startup secreta que quiere crear clones humanos sin cerebro (y ya hay inversores interesados)R3 Bio, a California startup, is developing a secret plan to create brainless human clones as organ reservoirs, with investors including Tim Draper. The company publicly claims to make primate organ bags, but internal documents reveal the broader goal. No human clones have been produced yet, and the project faces technical and ethical hurdles.MIT Technology ReviewInside the stealthy startup that pitched brainless human clonesR3 Bio, a stealth startup based in Richmond, California, has raised money from investors including Tim Draper, Singapore-based Immortal Dragons, and LongGame Ventures to develop nonsentient monkey organ sacks for testing, while MIT Technology Review discovered the company separately pitched the concept of creating brainless human clones as backup bodies for organ harvesting and potential body transplant procedures. The company's founder John Schloendorn is connected to the extreme longevity science community and has ties to ARPA-H through program manager Jean Hébert, with whom he has an informal collaboration on body replacement technology. A related stealth company called Kind Biotechnology, based in New Hampshire, is also developing similar organ-sack technology using CRISPR gene editing to create animals lacking brains, faces, or limbs.